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Abstract
Background: An estimated 20–30% of end-stage lung disease patients awaiting lung transplant die whilst on the
waiting list due to a shortage of suitable donor lungs. Ex-Vivo Lung Perfusion is a technique that reconditions donor
lungs initially not deemed usable in order to make them suitable for transplantation, thereby increasing the donor
pool. In this study, an economic evaluation was conducted as part of DEVELOP-UK, a multi-centre study assessing the
clinical and cost-effectiveness of the Ex-Vivo Lung Perfusion technique in the United Kingdom.
Methods: We estimated the cost-effectiveness of a UK adult lung transplant service combining both standard and Ex-
Vivo Lung Perfusion transplants compared to a service including only standard lung transplants. A Markov model was
developed and populated with a combination of DEVELOP-UK, published and clinical routine data, and extrapolated to
a lifetime horizon. Probabilistic sensitivity and scenario analyses were used to explore uncertainty in the final outcomes.
Results: Base-case model results estimated life years gained of 0.040, quality-adjusted life-years (QALYs) gained of 0.045
and an incremental cost per QALY of £90,000 for Ex-Vivo Lung Perfusion. Scenario analyses carried out suggest that an
improved rate of converting unusable donor lungs using Ex-Vivo Lung Perfusion, similar resource use post-transplant
for both standard and EVLP lung transplant and applying increased waiting list costs would reduce ICERs to
approximately £30,000 or below.
Conclusion: DEVELOP-UK base-case results suggest that incorporating Ex-Vivo Lung Perfusion into the UK adult lung
transplant service is more effective, increasing the number of donor lungs available for transplant, but would not
currently be considered cost-effective in the UK using the present NICE threshold. However, results were sensitive to
change in some model parameters and in several plausible scenario analyses results indicate that a service incorporating
Ex-vivo lung perfusion would be considered cost-effective .
Trial registration: ISRCTN registry number: ISRCTN44922411.
Date of registration: 06/02/2012.
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Background
Respiratory disease accounts for one in five deaths in the
UK [1]. Lung transplantation provides the only life
prolonging treatment option for a select few patients
with end-stage lung disease. Whilst not all those with
end stage lung disease might be suitable for lung trans-
plantation, a shortage of suitable donor lungs results in
around 20–30% of patients dying whilst on the lung
transplant (LTx) waiting list [2]. Although the number of
potential donors is limited, the primary cause of this
shortage is that approximately 80% of potential donor
lungs are felt to be unusable for standard LTx due to ir-
reversible pre-existing lung disease or by reversible dam-
age occurring during end-of-life care [3].
One solution to this problem is Ex-Vivo Lung Perfu-
sion (EVLP), a novel technique used to increase the
existing donor pool by assessing and reconditioning
donor lungs felt to be unusable in order to make them
clinically safe for LTx [4]. These donor lungs are at-
tached to the EVLP apparatus, ventilated, warmed to
body temperature and flushed with perfusate, donor
lungs are then assessed for suitability for transplant. The
first successful EVLP LTx took place in 2005 [5] and by
2014, around 350 EVLP transplants had taken place
worldwide [6]. Initial experience has shown that EVLP
can increase the number of LTxs by 15 to 30% [6]. How-
ever, a definitive study would be needed to establish the
safety, effectiveness and cost-effectiveness of this tech-
nique compared with standard transplant.
Summary of DEVELOP-UK
DEVELOP-UK was a multi-centre, unblinded, non-ran-
domized, non-inferiority observational study that sought
to evaluate the clinical- and cost-effectiveness of the
EVLP technique compared with standard lung trans-
plantation in the UK [4]. Participants were adults (≥18
years) who had already been accepted onto the UK LTx
waiting list. The target sample size was 306 in the stand-
ard transplant arm and 102 in the EVLP arm.
Non-inferiority was assumed if the hazard rate of death
during the first year was not more than doubled by the
use of EVLP.
Four hundred and eighty-seven participants were re-
cruited into the study, 202 received a LTx; 184 standard
and 18 EVLP. The small numbers in the EVLP arm led
to the study being terminated before the recruitment
targets were reached. Baseline characteristics of trans-
plant recipients in each arm are presented in Table 1.
Results of the study showed that a third of the donor
lungs subjected to EVLP were deemed suitable for trans-
plant (18 out of 53) representing a 10% increase in exist-
ing standard LTx activity due to EVLP transplants.
One-year survival in the EVLP arm was lower than in
the standard arm, 67% compared to 80%. However, the
non-inferiority definition of the study was satisfied. The
small numbers of individuals receiving transplants
means that the study was underpowered and non-infer-
iority was not established. An unexpected consequence
during the study was an increase in standard LTxs; one
centre witnessed an increase of 25%. Overall in the UK,
the increase in the number of LTxs was 6.9% in the first
year of the trial (2012/13), and the increase from
pre-trial was 20% in the second year (2013/14). In the
year after the trial finished (2014/15), the number of
transplants returned to almost pre-trial rates; an increase
of only 1.7% compared to the levels pre-trial [7]. The
proposed economic evaluation was a simple head-to-head
comparison of EVLP compared to standard lung trans-
plantation, not accounting for any spill-over effects. The
cost of an EVLP transplant was approximately £35,000
higher than a standard LTx, and quality-adjusted life-years
(QALYs) were similar in both arms twelve months after
transplantation [4].
The main outcome of DEVELOP-UK was survival at
12 months post-transplant. This was 0.67 (95% Confi-
dence Interval (CI) 0.4–0.83) in the EVLP arm and 0.80
(95% CI 0.74–0.85) in the standard arm. Given the mod-
est sample sizes a formal comparison was not attempted.
The mean cost of each EVLP procedure (recondition-
ing of donor lungs only) was approximately £14,500 per
patient. However, EVLP patients experienced increased
length of stay in the intensive care unit and needed more
lung support post-transplant resulting in increased
post-operative costs of £22,000 compared to standard
transplant. Overall the cost of an EVLP LTx was on aver-
age around £35,000 greater than a standard LTx (using a
1:1 conversion rate).
More detail on DEVELOP-UK results can be found in
the full study report [4].
Aims
The aim of this economic evaluation was to evaluate the
cost-utility of EVLP transplants within the current UK
National Health Service (NHS) LTx service, and to as-
sess whether including EVLP can ease waiting lists. A
model of the adult LTx service providing both standard
and EVLP transplants was compared with a service in-
cluding only standard transplants. The decision-analytic
model was populated with DEVELOP-UK, published
and clinical routine data.
Methods
Analysis overview
The target population was adults on the UK LTx waiting
list, while the perspective was the UK NHS. Following Na-
tional Institute for Health and Care Excellence (NICE)
guidelines, the time horizon used was lifetime to capture all
costs and outcomes over a patient’s lifetime, with a 3.5%
McMeekin et al. BMC Health Services Research          (2019) 19:326 Page 2 of 14







Gender Male n (%) 13 (72.2) 106 (57.6) 119 (58.9)
Female n (%) 5 (27.8) 78 (42.4) 83 (41.1)
Age (Years) n 18 183 201
Missing 0 1 1
Median 56 51 52
IQR 46–59 38–58 38–58
Range 20–64 18–70 18–70
Diagnosis COPD n (%) 5 (27.8) 40 (21.7) 45 (22.3)
Cystic Fibrosis n (%) 4 (22.2) 47 (25.5) 51 (25.2)
Interstitial Lung Disease n (%) 7 (38.9) 47 (25.5) 54 (26.7)
Emphysema n (%) 0 (0) 26 (14.1) 26 (12.9)
Non-CF Bronchiectasis n (%) 1 (5.6) 8 (4.3) 9 (4.5)
Obliterative Bronchiolitis n (%) 0 (0) 2 (1.1) 2 (1.0)
Pulmonary Hypertension n (%) 1 (5.6) 3 (1.6) 4 (2.0)
Other n (%) 0 (0) 9 (4.9) 9 (4.5)
Missing n (%) 0 (0) 2 (1.1) 2 (1.0)
Diabetes Yes n (%) 4 (22.2) 33 (18.1) 37 (18.3)
No n (%) 13 (72.2) 142 (78.0) 155 (76.7)
Missing n (%) 1 (5.6) 9 (3.9) 10 (5.0)
BMI n 17 182 199
Missing 1 2 3
Median 21.6 23.8 23.7
IQR 18.4–26.3 20.5–26.5 20.4–26.5
Range 17.6–32.5 15.4–34.2 15.4–34.2
FEV1 (L) n 15 176 191
Missing 3 8 11
Median 1.2 0.9 0.9
IQR 0.7–1.9 0.6–1.4 0.6–1.5
Range 0.5–2.5 0.3–3.6 0.3–3.6
FEV1% n 15 171 186
Missing 3 13 16
Median 29 26 27
IQR 22–50 20–45 20–45
Range 15–67 11–105 11–105
Type of Transplant Single n (%) 2 (11.1)* 24 (13.0)** 26 (13)
Bilateral n (%) 16 (88.9) 152 (82.6) 168 (83)
Missing n (%) 0 (0)
* 1 left, 1 right
8 (4.4)
**9 left, 13 right, 2 NK
8 (4)
Cardiopulmonary Bypass Use No n (%) 2 (11.1) 46 (25.0) 48 (24)
Yes n (%) 16 (88.9) 116 (63.0) 132 (65)
Not known n (%) 0 (0) 22 (12.0) 22 (11)
Source[4]
BMI body mass index, CF cystic fibrosis, COPD chronic obstructive pulmonary disease, EVLP Ex-vivo lung perfusion, FEV forced expiratory volume, IQR inter quartile
range, NK not known
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discount rate for both costs and health benefits [8].
Cost-effectiveness was measured against the current NICE
threshold of £20,000 to £30,000 per QALY [9].
Interventions were a UK adult LTx service combining
both EVLP and standard LTxs (‘EVLP service’) compared
to a standard LTx only service (‘Standard service’). These
interventions were chosen to illustrate the effect of
introducing EVLP into the existing UK LTx service as a
means of increasing the donor lung pool.
Model structure
A Markov model (Fig. 1) was developed using Microsoft®
Excel® 2010 (Microsoft, Washington, USA) to extrapolate
DEVELOP-UK results to a lifetime horizon. The model
represents the flow through the UK adult LTx service; be-
ginning in the ‘Waiting list’ state, the patient may remain or
progress to one of the following states; ‘Removed from the
waiting list’, ‘Death’; ‘Receiving a standard LTx’; or ‘Receiving
an EVLP LTx’. Post-transplant, the patient progresses either
to death or to the relevant post one-year transplant state.
Cycle length was 1 year reflecting the clinically important
first year following survival [10]. Costs and outcomes were
assigned to each model state.
Model transitions
Transitions from the waiting list were taken from figures
published by NHS Blood and Transplant (NHSBT) [11].
A cohort of 251 patients who registered for an LTx be-
tween 1 April 2011 and 31 March 2012, were followed
for 3 years, covering the same time period of DEVELOP-
UK trial. The numbers of patients who left the waiting
list each year were used to calculate transition rates.
Survival figures derived from DEVELOP-UK were not
deemed robust enough for use as a model parameter due
to the small number of participants in the EVLP arm and
the short period of follow-up (12months). Therefore, sur-
vival post-transplant was determined using NHSBT survival
data reported for a cohort of 348 patients who received
their LTx between 1 April 2004 and 31 March 2006 [12]
There is no evidence in the literature, nor from DEVELOP-
UK, of any difference in survival post-transplant between
standard and EVLP transplants [6], so the same survival
was assumed for both types of transplant. DEVELOP-UK
data showed a non-significant trend towards higher mortal-
ity for EVLP, however, it is important to note that due to
the small sample sizes in DEVELOP-UK the data are not
sufficiently comprehensive to permit a robust comparison.
One-year survival was used for ‘Year 1’ following both
standard and EVLP transplants. For post ‘Year 1’ states
an estimated mean post-transplant survival, which was
determined using area-under-the-curve methods pre-
cluding the need for tunnel states, was applied to each
transplant recipient. This was calculated using survival
data at 3, 5 and 10 years post-transplant and assuming
25 years to be maximum life expectancy post-transplant
(data from the International Society for Heart and Lung
Transplantation (ISHLT) report that for adults receiving
an LTx between January 1990 and June 2012 survival of
19 years post-transplant is 12% [13]).
Model assumptions
 The ‘Removed from waiting list’ state is an absorbing
state, where a patient does not accrue costs or
utilities (the probability attached to transitioning
into this state is independent of transplant type).
Patients transition to this state when they are too ill
to receive a transplant, prognosis is extremely poor
Fig. 1 Model structure
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for these patients, with survival typically less than a
month, Exploratory analysis was carried out to
estimate the effects of this assumption, by including
costs and QALYs for patients in this state and
varying the survival between 1, 3 and 6 months.
 NHSBT waiting list transitions were only available
for three years post-registration. As only 5% of the
cohort remained on the waiting list beyond three
years, it was assumed that transitions remain con-
stant from year three onwards.
 It was assumed that utilities at 12 months post-
transplant, derived from DEVELOP-UK data, were
the same for 2 years post-transplant and onwards.
This assumption is backed up by previous research
where utilities post double-lung transplant were
similar for 7–18 months (0.83), 19–36 months (0.81)
and > 36 months (0.82) [14].
Outcomes
The principle outcome measure used was QALYs, a
measure combining quality and length of life, calculated
using the patients’ responses to the 36-item Short Form
Health Survey (SF-36) [15]. DEVELOP-UK participants
completed SF-36 questionnaires whilst on the waiting
list and at 3 and 12 months post-transplant. SF-36 re-
sponses were converted into SF-6D scores using the
SF-6D algorithm; Values of 0 represent death, and 1 rep-
resents perfect health. Utility scores post-transplant were
combined with length of survival to calculate the esti-
mated QALYs for each patient [16]. Data were combined
for the EVLP and standard transplants giving health-
state specific utilities, not varying by type of transplant.
Costs
Costs were calculated based on resource use during
DEVELOP-UK [4]. Case report forms were used along
with expert opinion to identify resource use within eight
stages of lung transplantation; donor hospital, lung re-
trieval, transplant preparation, EVLP procedure, trans-
plant surgery, post-operative care, outpatient care, and
concomitant medications. Unit costs were obtained from
the British National Formulary(BNF) [17], Personal So-
cial Services Research Unit(PSSRU) [18], NHS reference
costs [19], Information Services Division Scotland(ISD)
[20], direct company quotes, expert opinion, hospital
costing tools and medical suppliers websites. The price
year used was 2016/2017 (and the currency was pounds
sterling (GBP, £).
Total mean cost per participant was calculated by
summing the products from unit costs multiplied by the
quantities of resources used, then dividing by the num-
ber of participants per arm.
To calculate the cost for the year of transplant all costs
listed above were included. For the years following,
transplant outpatient and medication costs were summed
and decreased annually in line with costs published by
Anyanwu and colleagues [14].
During DEVELOP-UK, 53 EVLP assessments were
completed resulting in 18 EVLP transplants, a conver-
sion rate of 53:18. To reflect this in the micro-costing
analysis, EVLP transplant costs were calculated by apply-
ing a 53:18 ratio to costs of the first four stages outlined
above as these stages are different between the two LTx
procedures. However, this ratio was not available for the
standard arm and therefore, this was considered to be
equal to 1:1.
Waiting list costs were not available using DEVELOP-
UK data and consequently they were obtained from a
published economic evaluation of adult lung transplant-
ation in the UK [14]. Costs for double lung transplant-
ation waiting list were used as 83% of transplants in
DEVELOP-UK were double-lung, and inflated to 2016/
2017 price year using the Hospital and Community
Health Services Index [21, 22].
Details of the costs used in the model can be found in
the DEVELOP-UK report [4].
Assessment of cost-effectiveness
An incremental cost-effectiveness ratio (ICER) was calcu-
lated by dividing the difference in total mean costs by the
difference in their mean outcomes between the two arms.
Uncertainty
Lack of robustness in DEVELOP-UK data as well as
model assumptions and parameters created uncertainty.
Because of this uncertainty, the use of point estimates to
populate the model would be potentially misleading. For
this reason, probabilistic sensitivity analysis (PSA) was
used to estimate mean costs and QALYs for the analysis.
Suitable distributions were assigned to each parameter
and de facto standard 1000 simulations were carried out.
Best practice was followed for PSA and the choice of pa-
rameters [23]. Model parameters and distributions are
listed in Table 2, and an incremental cost-effectiveness
plane and a cost-effectiveness acceptability curve
(CEAC) are presented. In Table 2 the key difference in
transition probabilities between EVLP and standard lung
transplant is that for any given time period there is a
10% increase in the number of transplants performed.
The impact of this in the model is that fewer patients
will die whilst on the waiting list or transfer off the wait-
ing list (into end of life care).
Scenario analysis investigated uncertainty by using
plausible alternative parameters and analysing the effect
on costs and utilities. Nine scenario analyses were car-
ried out. The first used NHSBT transition rates from be-
fore the trial. These rates were from a cohort of patients
added to the waiting list between 1 April 2008 and 31
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Table 2 Base case model parameters
Parameters Mean Alpha/Beta Distribution Source
Model transitions
From ‘Waiting list’ to ‘Removed from waiting list’ (Standard and EVLP service)
Year 1 0.020 5.02, 245.98 Beta NHSBT [11]
Year 2 0.030 2.51, 80.32 Beta NHSBT [11]
Year 3 onwards 0.077 2.51, 30.12 Beta NHSBT [11]
From ‘Waiting list’ to Transition to ‘Death’ (Standard and EVLP service)
Year 1 0.150 37.65, 213.35 Beta NHSBT [11]
Year 2 0.212 17.57, 65.26 Beta NHSBT [11]
Year 3 onwards 0.077 2.51, 30.12 Beta NHSBT [11]
From ‘Waiting list’ to ‘Receiving a standard lung transplant’
Year 1 0.510 128, 122.99 Beta NHSBT [11]
Year 2 0.364 30.1, 52.71 Beta NHSBT [11]
Year 3 onwards 0.462 15.1, 17.57 Beta NHSBT [11]
Increase in lung transplant activity due to EVLP procedure
(Applied in addition to standard LTx transition in EVLP service arm)
10% 18, 184 Beta DEVELOP-UK data [4]
Post lung transplant survival
One-year survival for standard and EVLP 0.77 257.91, 77.04 Beta UK cardio audit [27]
Area under the curve
1-year survival 0.77 257.91, 77.04 Beta UK cardio audit [27]
3-year survival 0.7 225.19, 96.51, Beta UK cardio audit [27]
5-year survival 0.53 167.15, 148.23 Beta UK cardio audit [27]
10-year survival 0.34 116.90, 226.93 Beta UK cardio audit [27]
Utilities
Waiting list 0.563 2292.2, 1782.4 Beta DEVELOP-UK data [4]
1-year post standard lung transplant 0.702 465.8, 197.3 Beta DEVELOP-UK data [4]
2 years onwards post standard lung transplant 0.734 439.7, 159.4 Beta DEVELOP-UK data [4]
1-year post EVLP lung transplant 0.702 465.8, 197.3 Beta DEVELOP-UK data [4]
2 years onwards post EVLP transplant 0.734 439.7, 159.4 Beta DEVELOP-UK data [4]
Costs
Waiting list cost per year £23,829 103.1, 239.3 Gamma Anyanwu [14]
Standard lung transplant £51,778 304.2, 175.5 Gamma DEVELOP-UK data [4]
EVLP lung transplant £137,527 98.4, 1441.1 Gamma DEVELOP-UK data [4]
Post lung transplant costs – standard LTx (outpatient and concomitant medication Table 38 HTA report[4])
Year 1 £9700 93.5, 107.1 Gamma DEVELOP-UK data [4]
Year 2 £3812 93.4, 42.1 Gamma DEVELOP-UK data [4]
Year 3 onwards £3506 93.4, 38.7 Gamma DEVELOP-UK data [4]
Post lung transplant costs – EVLP LTx
Year 1 £5919 20.2, 302.7 Gamma DEVELOP-UK data [4]
Year 2 £2326 20.2, 118.9 Gamma DEVELOP-UK data [4]
Year 3 onwards £2140 20.2, 109.4 Gamma DEVELOP-UK data [4]
N.B. All parameters used are for a double lung transplantation where data was available for both single and double lung transplant
*EVLP Ex-vivo lung perfusion, LTx Lung transplantation, NHSBT NHS blood and transplant
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March 2009 [24]. Using these transitions excludes any
effects that the change in retrieval procedure (for ex-
ample, unexpected increase in standard LTx) during
DEVELOP-UK may have had on transition rates. The
second scenario evaluated effects of raising transplant
activity due to EVLP to 20%, a conservative estimate [6].
The third and fourth scenarios altered the DEVELOP-
UK EVLP conversion rate (base-case: 53:18). A conver-
sion rate of 45% was chosen in the third scenario be-
cause prior to DEVELOP-UK the conversion rate was
anticipated to be 40–50%, while the fourth scenario used
a 1:1 rate to mirror the standard lung transplant conver-
sion rate used. No relevant published economic evalua-
tions of EVLP were found so there was no prior work
regarding retrieval to transplant conversion rates in this
area. The fifth scenario used published utilities from UK
LTx patients [25]. These utilities were for a larger cohort
than DEVELOP-UK; 87 waiting list patients; 255 trans-
plant recipients, and although only standard LTx patient
utilities were included, these were used for EVLP pa-
tients too. The sixth scenario excluded EVLP transplants
completely focussing instead on an unexpected increase in
standard LTx activity witnessed during DEVELOP-UK.
The seventh scenario replaced UK Cardiothoracic Trans-
plant Audit figures for 12-month survival post-transplant
with 12-month survival from DEVELOP-UK. The eighth
scenario used the same post-transplant inpatient care
costs in both arms to explore excluding the increase in
post-transplant inpatient costs seen in DEVELOP-UK, but
not reported in other EVLP settings [26]. The last scenario
increased the waiting list costs by 120%; waiting list costs
were taken from a UK study published in 2002, uplifted to
2016/17, waiting list costs are likely more expensive now
than when the 2002 study was carried out due to the avail-
ability of high costs therapeutics for cystic fibrosis (CF)
and idiopathic pulmonary fibrosis (IPF). Model parame-
ters and distributions used in all scenario analyses are pre-
sented in Table 3.
Ethics approval and consent to participate to DEVELOP-UK
Ethics approval was received from the National Research
Ethics Service (reference number 11/NE/0342) and NHS
research and development (R&D) approval was secured
prior to commencement of DEVELOP-UK. Local NHS
approvals were secured before recruitment commenced
at each site. The Newcastle Clinical Trials Unit, in its cap-
acity as study co-ordination centre, obtained a written copy
of local approval documentation before initiating each
centre and accepting participants into the study.
Results
Base-case results
Base-case cost-effectiveness results of the model-based
economic evaluation are presented in Table 4. The
incremental mean discounted lifetime cost of a LTx was
£4010 (95% CI £1863–£6723), higher in the ‘EVLP ser-
vice’. The incremental life-years gained 0.040 (95% CI
-0.011-0.101), higher in the ‘EVLP service’. Incremental
QALYs were 0.045 (95% CI 0.007–0.091) higher in the
‘EVLP service’. The incremental cost per life year gained
was £100,000 and the incremental cost per QALY gained
was £90,000 for the ‘EVLP service’ compared with the
‘Standard service’. 1% of simulations fall below the
£20,000 and £30,000 thresholds.
In the ‘Standard service’, the number of standard LTxs
carried out from a cohort of 1000 was 721. In the ‘EVLP
service’ the number of standard LTxs and EVLP LTxs
was 675 and 67 respectively, (742 in total). The number
of standard LTxs decreased in the ‘EVLP service’ com-
pared with the ‘Standard service’ as a result of the model
calculating transitions from the waiting list, as probabil-
ities. In other words, there are fewer patients left in the
‘Waiting list’ state at the end of each cycle in the ‘EVLP
service’ due to EVLP transplants, so less patients transi-
tion to receive a standard LTx.
Incremental costs and QALYs were plotted on an in-
cremental cost-effectiveness plane (Fig. 2). As can be
seen, most of the simulations fell in the north-east quad-
rant where the ‘EVLP service’ had higher costs and more
QALYs than the ‘Standard service’. A small number
(1.1%) of simulations fell in the north-west quadrant
where the ‘EVLP service’ had higher costs and lower
QALYs than the ‘Standard service’.
The CEAC (Fig. 3) illustrates that there is a 99.9 and
99.8% likelihood of the ‘Standard service’ being more
cost-effective than ‘EVLP service’ at a willingness-to-pay
of £20,000 and £30,000, respectively. At a willingness-
to-pay of £90,000, the ‘EVLP service’ begins to have a
higher probability of being more cost-effective than the
‘Standard service’.
Scenario analysis results
The scenario analysis results are presented in Table 5
below. The scenario analysis that resulted in the smallest
effect on the ICER was increasing the EVLP rate to 20%.
When the EVLP rate increased to 20%, costs and QALYs
increased but the ICER was virtually unchanged as the
increase in QALYs was negated by the proportionate in-
crease in costs. Nevertheless, the number of transplants
increased from 742 to 762 (2.6% increase).
Changing the conversion rate from base-case (53:18 or
35%) to 45% decreased the ICER to £65,000/QALY
gained. However, changing the conversion rate for EVLP
to 1:1 from the base-case of 53:18 resulted in an ICER of
£26,000/QALY which is at the upper end of what society
might be willing to pay for a QALY in the UK [8]. These
results are illustrated using a cost-effectiveness accept-
ability curve in Fig. 4 below.
McMeekin et al. BMC Health Services Research          (2019) 19:326 Page 7 of 14
Table 3 Scenario analysis parameters
Parameters Mean Alpha/Beta Distribution Source
Scenario 1: Pre-trial model transitions
From ‘Waiting list’ to ‘Removed from waiting list’ (Standard and EVLP service)
Year 1 0.08 16, 180 Beta NHSBT [24]
Year 2 0.03 2, 67 Beta NHSBT [24]
Year 3 onwards 0.11 3, 32 Beta NHSBT [24]
From ‘Waiting list’ to Transition to ‘Death’ (Standard and EVLP service)
Year 1 0.17 33,163 Beta NHSBT [24]
Year 2 0.09 6, 63 Beta NHSBT [24]
Year 3 onwards 0.17 6, 29 Beta NHSBT [24]
From ‘Waiting list’ to ‘Receiving a standard lung transplant’
Year 1 0.4 78, 118 Beta NHSBT [24]
Year 2 0.38 26, 43 Beta NHSBT [24]
Year 3 onwards 0.28 10, 25 Beta NHSBT [24]
Scenario 2: 20% increase in lung transplant activity due to EVLP procedure
Increase in LTx activity due to EVLP procedure
(Applied in addition to standard LTx transition in ‘EVLP service’ arm)
0.2 36, 184 Beta DEVELOP-UK data [4]
Scenario 3: 45% Conversion rate
EVLP lung transplant £119,672 75.1, 1644.4 Gamma DEVELOP-UK data [4]
Scenario 4: 1:1 conversion rate
EVLP lung transplant £89,455 42.4, 2174.3 Gamma DEVELOP-UK data [4]
Scenario 5: Utilities from literature
Waiting list 0.31 59.72, 132.93 Beta Anyanwu et al. [25]
1-year post standard lung transplant 0.83 1099.12, 257.82 Beta Anyanwu et al. [25]
2 years onwards post standard lung transplant 0.82 854.12, 187.49 Beta Anyanwu et al. [25]
1-year post EVLP lung transplant 0.83 1099.12, 257.82 Beta Anyanwu et al. [25]
2 years onwards post EVLP transplant 0.82 854.12, 187.49 Beta Anyanwu et al. [25]
Scenario 6: Increase in LTx activity (Excluding EVLP)
Pre-trial
From ‘Waiting list’ to ‘Removed from waiting list’
Year 1 0.08 16, 180 Beta NHSBT [11]
Year 2 0.03 2, 67 Beta NHSBT [11]
Year 3 onwards 0.11 3, 32 Beta NHSBT [11]
From ‘Waiting list’ to Transition to ‘Death’
Year 1 0.17 33,163 Beta NHSBT [11]
Year 2 0.09 6, 63 Beta NHSBT [11]
Year 3 onwards 0.17 6, 29 Beta NHSBT [11]
From ‘Waiting list’ to ‘Receiving a standard lung transplant’
Year 1 0.40 78, 118 Beta NHSBT [11]
Year 2 0.38 26, 43 Beta NHSBT [11]
Year 3 onwards 0.28 10, 25 Beta NHSBT [11]
Within trial
From ‘Waiting list’ to ‘Removed from waiting list’
Year 1 0.020 5.02, 245.98 Beta NHSBT [24]
Year 2 0.030 2.51, 80.32 Beta NHSBT [24]
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In Scenario 8, when we used the same costs for
post-transplant care (as reported in other EVLP set-
tings), the ICER decreases to £34,000. Increasing the
waiting list cost by 120% resulted in an ICER of
£26,000/QALY. The scenario with the lowest ICER was
Scenario 6; evaluating the unexpected increase in LTx
during the trial, and this resulted in an ICER of
£20,000/QALY. The scenario with the greatest effect on
the ICER was scenario 7, resulting in an ICER of
£408,000/QALY.
Exploratory analysis
As pointed out in the Results section 3.1, the number of
standard LTxs will differ between the two services after the
first cycle as a result of the increase in transplants due to
EVLP transplants. An exploratory analysis was carried out
to estimate the effect on the ICER of relaxing this conserva-
tive assumption. If adopting a service including EVLP in-
creased the number of EVLP lungs and at least maintained
the number of standard lungs transplanted then the net
cost per patient compared to not being transplanted would
be £56,200 and the mean gain in QALYs would be 4.09. As-
suming there would be an extra 46 standard transplants
(based on the above exploratory analysis), then the incre-
mental cost of service including both standard and EVLP
transplants, compared with a service comprising just stand-
ard LTxs, would be £29,000 per patient, considered
cost-effective.
Table 3 Scenario analysis parameters (Continued)
Parameters Mean Alpha/Beta Distribution Source
Year 3 onwards 0.077 2.51, 30.12 Beta NHSBT [24]
From ‘Waiting list’ to Transition to ‘Death’
Year 1 0.150 37.65, 213.35 Beta NHSBT [24]
Year 2 0.212 17.57, 65.26 Beta NHSBT [24]
Year 3 onwards 0.077 2.51, 30.12 Beta NHSBT [24]
From ‘Waiting list’ to ‘Receiving a standard lung transplant’
Year 1 0.510 128, 122.99 Beta NHSBT [24]
Year 2 0.364 30.1, 52.71 Beta NHSBT [24]
Year 3 onwards 0.462 15.1, 17.57 Beta NHSBT [24]
Scenario 7: DEVELOP-UK one-year survival post-transplant
Standard service 0.80 161.8, 40.4 Beta DEVELOP-UK [4]
EVLP service 0.67 11.64, 5.73 Beta DEVELOP-UK [4]
Scenario 8: Same costs of post-transplant inpatient care in both arms (EVLP service = standard service costs plus costs of EVLP procedure)
Standard service transplant £51,778 304.2, 175.5 Gamma DEVELOP-UK data [4]
EVLP service transplant £95,750 344.74, 269.29 Gamma DEVELOP-UK data [4]
Scenario 9: Increase in waiting list costs by 120%
Increase waiting list cost £50,830 96.04, 529.26 Gamma 120% increase
*EVLP Ex-vivo lung perfusion, LTx Lung transplantation, NHSBT NHS blood and transplant
Table 4 Base-case cost-effectiveness results
‘Standard Service’ ‘EVLP service’
Discounted Mean costs £69,954 £73,964
Mean life-years gained 5.62 5.66




ICER Life-years gained £100,000
QALYs £90,000
Number of Standard lung transplants 721 675
EVLP transplants 67
*EVLP Ex-vivo lung perfusion, ICER Incremental costs-effectiveness ratio, QALYs Quality-adjusted life-years ICER incremental cost-effectiveness ratio
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Our second exploratory analysis relaxes the base-case as-
sumption that costs and QALYs are not accrued to patients
removed from the waiting list. The results and parameters
from this exploratory analysis are presented in Table 6
below. Six more patients were removed from the waiting
list in the ‘Standard service’ compared to ‘EVLP service’. In-
cluding the costs and QALYs of these patients does not
affect the results; the ICER remains at £90,000/QALY.
Discussion
Main findings
According to the findings of the study, the estimated
ICER for the EVLP procedure was £90,000/QALY sug-
gesting that at the current NHS cost-effectiveness
threshold, the ‘EVLP service’ would not be considered
cost-effective [9], although it might be approved based
on the NICE end-of-life criteria [8]. In the scenario ana-
lyses, the estimated ICERs were relatively stable for
pre-trial transitions and EVLP rate adjustment. Chan-
ging the conversion rate (of substandard lungs to trans-
plantable lungs) to 45% and using utilities identified
from the literature increased the change in the ICER.
The greatest variation on ICERs was using DEVELOP-
UK one-year survival post-transplant, however, it should
be noted that no evidence of a difference in survival be-
tween EVLP and standard LTx has been reported in pre-
vious trials. Four scenario analyses suggested that an
EVLP service might be considered cost-effective, the
Fig. 2 Incremental cost-effectiveness plane: base-case analysis
Fig. 3 Cost-effectiveness acceptability curve: base-case analysis
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ICER was reduced to below £30,000 for three of these:
when applying only the increase in standard LTx wit-
nessed during the trial, assuming a 1:1 conversion rate
and increasing waiting list costs by 120%. Applying simi-
lar costs post-transplant forboth transplant types, as wit-
nessed in other EVLP settings, resulted in an ICER of
£34,000 suggesting that an EVLP service might be con-
sidered cost-effective.
The increase in standard transplants during the
DEVELOP-UK study suggests that having access to the
EVLP procedure increased recovery rates for what would
previously have been deemed substandard lungs but
were subsequently found to be suitable for standard
transplant. The lesson is that many lungs that might ini-
tially be deemed unusable on referral may be deemed
suitable on closer inspection using standard methods
alone and without need for EVLP. However, this should
be viewed with caution as the increase in standard LTx
rates during the trial may have also resulted from other
non-defined factors. EVLP assessments that did not re-
sult in a transplant were included in the study costs,
however, this method was not adopted for the standard
lung recovery as this information was not available. In-
cluding the costs of retrieving lungs that were not used
for standard LTx could potentially alter the ICER be-
tween the two transplant procedures. The conversion
rate for EVLP witnessed during the DEVELOP-UK study
(53:18) was lower than the anticipated (40–50%) and
lower than the two previous largest EVLP trials, which
had conversion rates of 86% [30] from 58 EVLP assess-
ments and 82% from 125 assessments [31]. The low con-
version rate is likely a result of issues with donor lung
Table 5 Scenario analysis results
Scenario number Without EVLP With EVLP ICER
Cost LYG QALYs Standard
LTx








Base-case £69,954 5.620 3.669 721 £73,964 5.660 3.714 675 67 £100,000 £90,000
1) Pre-trial transitions & 10% £
65,778
5.153 3.304 620 £69,265 5.199 3.354 586 59 £75,000 £71,000
2) EVLP rate 20% £69,990 5.613 3.663 721 £77,128 5.691 3.747 635 127 £91,000 £85,000
3) Conversion rate 45% £70,014 5.631 3.679 721 £73,014 5.673 3.725 675 67 £71,000 £65,000
4) 1:1 conversion rate £70,136 5.634 3.675 721 £71,300 5.675 3.720 675 67 £28,000 £26,000
5) Utilities from literature £69,851 5.606 3.937 721 £73,941 5.647 4.020 675 67 £98,000 £49,000
6) Increase in standard LTx in trial £65,439 5.010 3.200 620 £73,377 5.500 3.590 721 0 £16,000 £20,000
7) DEVELOP-UK one-year survival post-
transplant
£72,050 5.630 3.670 721 £76,128 5.620 3.680 675 67 Standard
dominant
£408,000
8) Same post-transplant costs plus EVLP
process costs in EVLP arm
£69,970 5.631 3.673 721 £71,569 5.674 3.720 675 67 £37,000 £34,000
9) Increased waiting list costs (120%) £82,531 5.628 3.674 721 £83,742 5.671 3.721 675 67 £28,124 £25,855
*EVLP Ex-vivo lung perfusion, ICER Incremental cost-effectiveness ratio, LYG Life-years gained, LTx Lung transplant, QALYs Quality-adjusted life-years
Fig. 4 Cost-effectiveness acceptability curve: varying conversion rates
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selection for EVLP, the inflexibility of the multi-centre
protocol. Furthermore within the context of a multicen-
tre clinical trial donor lung selection is predefined
whereas data drawn from the experience of a single
centre are likely to be more selective in the choice of
donor to perform EVLP on.
Strengths and limitations
This is the first known economic evaluation of the EVLP
technique for lung transplantation based on a
multi-centre study. The strengths of this study were that
all parameters used in the model were based on the UK
adult LTx population. In addition, International Society
for Pharmacoeconomics and Outcomes Research guide-
lines [32] were followed when designing the model
reflecting best practice, while uncertainty in the data was
evaluated using both deterministic and probabilistic sen-
sitivity analyses. Finally, the DEVELOP-UK population is
the general UK population as the study included a major
proportion (> 70%) of all the lung transplantation activity
over a two-year period. Therefore, the conclusions are
totally relevant to UK practice.
The main limitation of the study was the low number
of EVLP transplants during DEVELOP-UK meaning the
outcome and use of services consequent to EVLP was
imprecise and potentially unreliable. However, in the
absence of other EVLP LTx data, and with
DEVELOP-UK data subjected to PSA, deterministic ana-
lysis and scenario analysis, this study presents useful evi-
dence on the potential for the EVLP technique. Evidence
of higher resource use post-transplant by EVLP lung re-
cipients in DEVELOP-UK has not been witnessed else-
where, however this was explored in the scenario
analyses by using similar costs post-transplant for both
types of transplant. One model assumption was that
when a patient in the ‘Waiting list’ state transitioned to
the ‘Removed from waiting list’ state, no further costs or
benefits were incurred. This assumption is the same as
assumptions made in a Dutch economic evaluation of
LTx service [33]. The cause of a removal is not known
but it is reasonable to presume that most patients
will be removed due to declining health. This, how-
ever, would result in higher costs and lower utilities
until death. As a result, the costs are potentially
underestimated and utilities overestimated in both
arms; the net impact on cost-effectiveness is not pos-
sible to be predicted without information to model
the costs and utilities of patients who are removed
from the waiting list, however, this was mitigated by
conducting the exploratory analysis which found in-
cluding costs and utilities in the removed from wait-
ing list state did not alter the ICER.
Table 6 Results of including patients who are removed from the waiting list
Results of exploratory analysis
Without EVLP With EVLP
Survival after removal from waiting list Cost QALYs Cost QALYs ICER Cost source QALY source
One month £69,955 3.67 £73,964 3.71 £90,000 Dzingina [28] DEVELOP-UK [4]
£69,955 3.67 £73,964 3.71 £90,000 Dzingina [28] Anyanwu [14]
£69,956 3.67 £73,964 3.71 £90,000 Georghiou [29] DEVELOP-UK [4]
£69,956 3.67 £73,964 3.71 £90,000 Georghiou [29] Anyanwu [14]
Three months £69,958 3.67 £73,964 3.71 £90,000 Dzingina [28] DEVELOP-UK [4]
£69,958 3.67 £73,964 3.71 £90,000 Dzingina [28] Anyanwu [14]
£69,959 3.67 £73,964 3.71 £90,000 Georghiou [29] DEVELOP-UK [4]
£69,959 3.67 £73,964 3.71 £90,000 Georghiou [29] Anyanwu [14]
Six months £69,961 3.67 £73,964 3.71 £90,000 Dzingina [28] DEVELOP-UK [4]
£69,961 3.67 £73,964 3.71 £90,000 Dzingina [28] Anyanwu [14]
£69,964 3.67 £73,964 3.71 £90,000 Georghiou [29] DEVELOP-UK [4]
£69,964 3.67 £73,964 3.71 £90,000 Georghiou [29] Anyanwu [14]
Parameters
Source Disease area Parameter type Parameter value
Dzingina 2017 Advanced chronic disease Palliative care cost per month £1173
Georghiou 2014 Any palliative care Palliative care cost per month £1644
DEVELOP-UK Lung transplant Quality adjusted life-years 0.563
Anyanwu Lung transplant Quality adjusted life-years 0.31
*EVLP Ex-vivo lung perfusion, ICER Incremental cost-effectiveness ratio, QALYs Quality-adjusted life-years
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The use of published utility rates resulted in the third
largest impact on the ICER of the sensitivity analyses re-
ported. However, caution should be exercised as the
published utilities came from a 1998 cohort, since then
care for patients, as well as the criteria for registering on
the LTx waiting list may have changed. Waiting list costs
used in the base-case analysis were taken from the same
cohort and are unlikely to reflect the increased use of
high cost therapies for CF and IPF available when
DEVELOP-UK was conducted. The authors were unable
to locate more recent UK waiting list costs for use in the
model. Around 50% of the DEVELOP-UK cohort had ei-
ther CF or IPF, however, so waiting list costs during
DEVELOP-UK were likely higher, a scenario analysis
was conducted to explore the effect on the ICER of in-
creased waiting list costs.
It should be noted that this evaluation is based on the
UK LTx service and associated costs, therefore, whilst
the model could be applied in other jurisdictions, the
analysis may have limited applicability to health systems
with a markedly different cost structure to the UK. The
underpinning resource use data (available from the au-
thors) may be more transferable.
Comparison to other clinical evidence and future research
Despite a literature search, the authors are unaware of
any other cost-effectiveness studies of EVLP LTx com-
pared to standard LTx. One UK-based study was identi-
fied,from 1999, comparing standard LTx to medical
treatment, This study reported total costs of £110,078
[14]. This is higher than the £69,954 mean standard
LTx cost in our study, most of this difference results
from higher post-transplant costs in the 1999 paper.
This difference is likely due to several factors; early
post-transplant results are better now than 20 years
ago, as is overall survival and LTx centres are, when the
patients are stable, also more comfortable with less fre-
quent (and hence less costly) follow-up compared to
20 years ago.
This study has highlighted the need for more research
in this area. Of particular interest are post-operative care
resources, utilities and survival of EVLP recipients.
Conclusion
The aim of the economic evaluation of the DEVELOP-
UK study was to determine the cost-effectiveness of a
UK adult LTx service including EVLP compared to one
without, and the objective of including EVLP was to in-
crease the pool of donor lungs. The results of this study
suggest that combining EVLP with standard transplants
increases the number of transplants, thereby reducing
numbers on the waiting list. However, with the increased
cost of transplant due to the EVLP procedure and the
increased post-operative care costs the EVLP service is
unlikely to currently be considered cost-effective, unless
EVLP is deemed within the NICE remit for end-of-life
care. Nevertheless, with an improved conversion rate,
nearer to those witnessed in previous trials [30, 31], with
a lower complication rate post-transplant for EVLP
transplants, witnessed in other EVLP settings, and with
higher waiting list costs, including EVLP in the UK LTx
service the picture could be very different.
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